Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
322,637
result(s) for
"Prostate"
Sort by:
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Guiding the beta-emitting isotope lutetium-177 to prostate cancer lesions with the prostate-specific membrane antigen–targeted radioligand
177
Lu-PSMA-617 plus using standard care was compared with standard care in patients with metastatic castration-resistant prostate cancer. The radioligand therapy prolonged progression-free and overall survival. Adverse effects were more common, but quality of life was maintained.
Journal Article
Dr. Patrick Walsh's guide to surviving prostate cancer
\"Each year, more than 230,000 men are diagnosed with prostate cancer, and 30 to 40 percent of patients who are diagnosed will eventually relapse. But the good news is that more men are being cured of this disease than ever before. Now in a revised third edition, this lifesaving guide by Dr. Patrick Walsh and award-winning science writer Janet Farrar Worthington offers a message of hope to every man facing this illness. Prostate cancer is a different disease in every man, which means that the right treatment varies for each man. Readers will discover their risk factors, simple changes that can reduce the risk of developing the disease, treatment options, and more\"--Amazon.com.
Book
Results after Four Years of Screening for Prostate Cancer with PSA and MRI
After 4 years of the GÖTEBORG-2 trial, MRI-targeted biopsy led to less detection of clinically insignificant prostate cancer than systematic biopsy without compromising the detection of cancer that may affect survival.
Journal Article
Cooking well. Prostate health
\"More than 30 million men suffer from prostate conditions that negatively affect their quality of life. While family history and aging are the biggest factors of declining prostate health, diet plays an essential role in both prevention and managing prostate problems. Studies show that people who eat a high fat diet have a greater risk of developing prostate cancer. On the other hand, fiber, soy protein, fruits, and cooked tomatoes have all been shown to reduce risk. Cooking Well: Prostate Health features over 100 healthy and delicious recipes that are specifically designed to reduce the risk of prostate problems. It also provides a basic understanding of the prostate and the most common ailments as well as a list of foods to avoid. All recipes and meals in the \"Cooking Well\" series have been specially created by renowned health and diet experts. Each book in the series also includes general nutrition information as well as tips on which foods to avoid along the path of nutritional healing\"-- Provided by publisher.
Book
MRI-Targeted or Standard Biopsy in Prostate Cancer Screening
Population-based screening showed that men over age 50 with PSA of 3 ng per milliliter or higher and negative MRI results could safely forgo biopsy. Detection of clinically significant cancer among men with positive MRI results who underwent MRI-directed and standard biopsies was similar to that for the standard biopsy group, but the MRI group had fewer findings of clinically insignificant cancers.
Journal Article
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
In men with prostate cancer on PSA screening, radical treatments led to half the incidence of metastasis and local progression as active monitoring without affecting disease-specific or overall survival.
Journal Article
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
A randomized trial showed noninferiority of stereotactic body radiotherapy to conventionally or moderately hypofractionated radiotherapy in preventing biochemical recurrence in selected men with localized prostate cancer.
Journal Article
Radical Prostatectomy versus Observation for Localized Prostate Cancer
Over 700 men were assigned to radical prostatectomy or observation after receiving a diagnosis of prostate cancer, usually on the basis of elevated PSA levels. After a median of 10 years, between-group differences in all-cause and prostate-cancer mortality were not significant.
The treatment of early-stage prostate cancer remains controversial, especially for tumors detected by means of prostate-specific antigen (PSA) testing.
1
Systematic reviews have provided inadequate information for assessing the comparative effectiveness of treatments and any associated harms.
2
Although the lifetime risk of receiving a diagnosis of prostate cancer is about 17%, the risk of dying from the disease is approximately 3%, suggesting that conservative management may be appropriate for many men.
3
,
4
Two randomized trials compared radical prostatectomy with observation but were conducted before PSA testing became widespread.
5
,
6
One study failed to show a significant difference in overall mortality after . . .
Journal Article